Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of intravenous difelikefalin in adolescents on hemodialysis with moderate-to-severe CKD-associated pruritus
MOH_2024-09-09_013531Phase 3Not yet recruiting
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Start
- Sep 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of difelikefalin in chronic kidney disease (CKD), sponsored by Vifor Fresenius Medical Care Renal Pharma. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2024-09-09_013531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-09_013531.